Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Allogene Therapeutics revenue
Allogene Therapeutics's revenue is $95,000.
What is Allogene Therapeutics's revenue?
- Allogene Therapeutics's revenue growth from 2021 to 2023 is -99.75%.
- Allogene Therapeutics has 289 employees, and the revenue per employee ratio is $328.
- Allogene Therapeutics's peak quarterly revenue was $75.8M in 2021(q4).
- Allogene Therapeutics peak revenue was $38.5M in 2021.
- Allogene Therapeutics annual revenue for 2022 was 243.0K, -99.37% growth from 2021.
- Allogene Therapeutics annual revenue for 2023 was 95.0K, -60.91% growth from 2022.
On this page
Zippi applies for you, and finds you a job.
Allogene Therapeutics historical revenue
Allogene Therapeutics's peak revenue was $38.5M in 2021. The peak quarterly revenue was $75.8M in 2021(q4).
Allogene Therapeutics's revenue increased from $38.5m in 2021 to $95.0K currently. That's a -99.75% change in annual revenue.
Allogene Therapeutics annual revenue
Allogene Therapeutics annual revenue over time
| Fiscal year / year | Allogene Therapeutics revenue |
|---|---|
| 2021 | $38.5M |
| 2022 | $243,000 |
| 2023 | $95,000 |
Allogene Therapeutics quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Allogene Therapeutics quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2021 | $38.3M | $44,000 | $49,000 | $75.8M |
| 2022 | $61,000 | $86,000 | $49,000 | $47,000 |
| 2023 | $30,000 | $22,000 | $22,000 | $21,000 |
| 2024 | $22,000 | - | - | - |
Allogene Therapeutics jobs nearby
Do you work at Allogene Therapeutics?
Did Allogene Therapeutics meet its revenue projections?
Allogene Therapeutics financial information
| CEO | David Chang |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 289 |
| Date Founded | 2017 |
| Headquarters | South San Francisco, California |
| Number of Locations | 2 |
| Revenue | $95,000 |
| Net Income | -$332,632,000 |
| Tax Rate | 0.0% |
| Total Assets | $817,079,000 |
| Ticker | ALLO |
Allogene Therapeutics jobs you might like
Allogene Therapeutics financing
Allogene Therapeutics received early financing of $411.8M on 2018-04-19.
| Series | Round size | Date |
|---|---|---|
| Series A | $411.8M | 04/2018 |
| Convertible Note | $120M | 09/2018 |
| Convertible Note | $120M | 09/2018 |
Allogene Therapeutics investors
| Investors | Security type |
|---|---|
| Two River | Series A |
| Vida Ventures LLC | Series A |
| Bellco Capital | Series A |
| Gilead Sciences | Series A |
| TPG | Series A |
| Pfizer, Inc. | Series A |
| Jennison Associates | Convertible Note |
| Franklin Resources | Convertible Note |
| Perceptive Advisors | Convertible Note |
| venBio Select Advisor | Convertible Note |
| T. Rowe Price | Convertible Note |
| Fidelity Management & Research Co LLC | Convertible Note |
| Deerfield Capital Management | Convertible Note |
| Surveyor Capital | Convertible Note |
Allogene Therapeutics competitors
Allogene Therapeutics's top competitor, TCR² Therapeutics, earned an annual revenue of $661.1M.
Allogene Therapeutics's smallest competitor is Eureka Therapeutics with revenue of $500.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Fate Therapeutics | - | $13.6M | 104 | - |
| Atara Biotherapeutics | - | $128.9M | 578 | - |
| Poseida Therapeutics | - | $64.7M | 200 | - |
| BioTime | - | $3.4M | 101 | - |
| Eureka Therapeutics | - | $500,000 | 50 | - |
| Adaptimmune | - | $178.0M | 452 | - |
| TCR² Therapeutics | - | $661.1M | 118 | - |
| Cabaletta Bio | - | $1.6M | 20 | - |
| G1 Therapeutics | - | $82.5M | 148 | - |
| Arcellx | - | $107.9M | 1 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Allogene Therapeutics highest paying jobs
Zippia gives an in-depth look into the details of Allogene Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Allogene Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Allogene Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Allogene Therapeutics. The data presented on this page does not represent the view of Allogene Therapeutics and its employees or that of Zippia.
Allogene Therapeutics may also be known as or be related to ALLOGENE THERAPEUTICS, INC., Allogene Therapeutics, Allogene Therapeutics Inc, Allogene Therapeutics Inc. and Allogene Therapeutics, Inc.